Wessell Aaron, Kole Matthew J, Badjatia Neeraj, Parikh Gunjan, Albrecht Jennifer S, Schreibman David L, Simard J Marc
Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD, United States.
Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, United States.
Front Neurol. 2017 Jun 9;8:268. doi: 10.3389/fneur.2017.00268. eCollection 2017.
We sought to determine whether compliance with scheduled nimodipine in subarachnoid hemorrhage patients impacted patient outcomes, with the intent of guiding future nimodipine management in patients who experience nimodipine-induced hypotension.
We performed a retrospective analysis of 118 consecutive aneurysmal subarachnoid hemorrhage patients treated with the Maryland Low-Dose IV Heparin Infusion Protocol. Patients were categorized into three independent nimodipine compliance groups: ≥1 dose held, ≥1 dose split, and no missed or split-doses. A split-dose was defined as 30 mg of nimodipine administered every 2 h. Our primary outcome was discharge to home. Bivariate and multivariable logistic regression analyses were used to assess predictors of discharge disposition as a function of nimodipine compliance.
Of the 118 patients, 20 (17%) received all nimodipine doses, 6 (5%) received split-doses but never had a full dose held, and 92 (78%) had ≥1 dose held. Forty-five percent of patients were discharged to home, including 75% who received all doses, 67% who received ≥1 split-doses, and 37% with ≥1 missed doses ( = 0.003). Multivariable analysis showed that, along with age and World Federation of Neurosurgical Societies grade, nimodipine compliance was an independent predictor of clinical outcome; compared to missing one or more nimodipine doses, full dosing compliance was associated with increased odds of discharge to home (odds ratio 5.20; 95% confidence intervals 1.46-18.56).
In aneurysmal subarachnoid hemorrhage patients with modified Fisher scores 2 through 4 who are cotreated with a low-dose heparin infusion, full compliance with nimodipine dosing was associated with increased odds of discharge to home.
我们试图确定蛛网膜下腔出血患者按时服用尼莫地平是否会影响患者的预后,目的是为经历尼莫地平引起的低血压的患者未来的尼莫地平管理提供指导。
我们对118例接受马里兰低剂量静脉肝素输注方案治疗的连续性动脉瘤性蛛网膜下腔出血患者进行了回顾性分析。患者被分为三个独立的尼莫地平依从性组:≥1剂未服用、≥1剂分服、无漏服或分服。分服剂量定义为每2小时服用30毫克尼莫地平。我们的主要结局是出院回家。采用双变量和多变量逻辑回归分析来评估作为尼莫地平依从性函数的出院处置预测因素。
在118例患者中,20例(17%)服用了所有尼莫地平剂量,6例(5%)接受了分服剂量但从未有过整剂未服用的情况,92例(78%)有≥1剂未服用。45%的患者出院回家,包括75%服用了所有剂量的患者、67%接受了≥1次分服剂量的患者和37%有≥1剂漏服的患者(P = 0.003)。多变量分析表明,除年龄和世界神经外科联合会分级外,尼莫地平依从性是临床结局的独立预测因素;与漏服一剂或多剂尼莫地平相比,完全服药依从性与出院回家的几率增加相关(比值比5.20;95%置信区间1.46 - 18.56)。
在采用低剂量肝素输注联合治疗的改良Fisher评分为2至评分4的动脉瘤性蛛网膜下腔出血患者中,完全依从尼莫地平给药与出院回家的几率增加相关。